ABVC BioPharma, Inc.
ABVC
$0.742
-$0.1725-18.86%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -32.30% | -82.19% | -97.63% | -84.28% | 115.48% |
| Total Other Revenue | -41.51% | -- | -- | -- | -- |
| Total Revenue | -31.04% | -82.19% | -97.63% | -84.28% | 115.48% |
| Cost of Revenue | -67.30% | -58.64% | -29.77% | 5.45% | 1,699.16% |
| Gross Profit | 18.94% | -109.21% | -129.78% | -121.89% | -2.57% |
| SG&A Expenses | -10.11% | -5.46% | -1.35% | -46.55% | -58.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -256.48% | -- | -- | -- | -- |
| Total Operating Expenses | -32.67% | -25.86% | -17.55% | -47.90% | -45.99% |
| Operating Income | 32.80% | 21.93% | 9.60% | 45.57% | 49.00% |
| Income Before Tax | 21.61% | -3.91% | -13.35% | 31.33% | 38.22% |
| Income Tax Expenses | -93.79% | -93.95% | -71.06% | -67.91% | 23.34% |
| Earnings from Continuing Operations | 27.84% | 4.31% | -7.20% | 33.12% | 35.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 353.47% | 447.62% | 385.02% | 456.14% | 75.96% |
| Net Income | 32.81% | 10.13% | -3.05% | 35.97% | 37.06% |
| EBIT | 32.80% | 21.93% | 9.60% | 45.57% | 49.00% |
| EBITDA | 32.92% | 22.01% | 9.60% | 45.67% | 49.09% |
| EPS Basic | 72.35% | 53.76% | 36.80% | 51.75% | 48.99% |
| Normalized Basic EPS | 72.24% | 52.17% | 35.27% | 51.96% | 52.60% |
| EPS Diluted | 72.09% | 53.61% | 36.68% | 51.65% | 48.99% |
| Normalized Diluted EPS | 72.24% | 52.17% | 35.27% | 51.96% | 52.60% |
| Average Basic Shares Outstanding | 187.16% | 141.18% | 82.86% | 36.99% | 17.78% |
| Average Diluted Shares Outstanding | 187.16% | 141.18% | 82.86% | 36.99% | 17.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
